1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
COSMOS Pharmaceutical Corporation

COSMOS Pharmaceutical Corporation

CSMYF
COSMOS Pharmaceutical CorporationUS flagOther OTC
37.06
USD
- -
- -
2.94BMarket Cap
COSMOS Pharmaceutical Corporation
CSMYF
(Other OTC)

Recent

price

37.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,593.26
2,994.63
3,523.02
4,158.03
4,694.82
5,157.49
5,647.5
6,347.76
7,045.6
7,716.55
8,641.64
9,172.23
9,538.29
10,451.02
12,178.18
12,761.05
6,164.14
Revenue per Share
59.49
72.44
97.69
118.64
133.84
147.65
157.01
229.99
222.64
242.24
270.65
342.89
292.37
300.48
308.61
390.86
162.34
Basic EPS, GAAP
51.45
94.52
62.59
9.28
73.46
-131.45
-1.34
104.43
39.58
67.41
498.91
22.87
-142.72
98.46
-8.01
-10.84
- -
Free Cash Flow per Basic Share
3.75
5.74
13.25
10.49
13.74
14.37
15.62
17.49
22.49
22.49
26.23
28.75
41.24
41.24
58.8
62.57
- -
Dividend per Share
252.9
319.6
404.04
512.19
632.29
766.76
908.14
1,120.64
1,320.79
1,540.53
1,784.93
2,099.08
2,350.21
2,609.46
2,857.96
3,185.71
3,009.31
Book Value per Share
302.11
366.81
449.44
557.43
678.29
815.24
957.68
1,172.22
1,371.15
1,590.97
1,835.99
2,149.7
2,399.98
2,658.22
2,914.53
3,242.87
3,066.34
Tangible Book Value per Share
79
79
79
79
79
79
79
79
79
79
79
79
79
79
79
79
79
Basic Weighted Avg Shares
205,387
237,174
279,021
329,313
371,825
408,466
447,273
502,732
557,999
611,137
684,403
726,424
755,414
827,697
964,989
1,011,390
488,559
Sales/Revenue/Turnover
3.77
4.23
4.78
4.72
4.49
4.18
4.17
4.42
4.08
4.05
4.25
4.56
3.94
3.64
3.26
3.99
3.21
Operating Margin (%)
1,857
2,362
3,104
4,247
5,604
7,342
9,588
10,710
11,885
12,958
13,562
13,785
15,110
17,368
19,924
22,229
- -
Depreciation Expense
4,712
5,737
7,737
9,396
10,600
11,694
12,435
18,215
17,633
19,185
21,435
27,156
23,155
23,797
24,454
30,978
12,867
Net Income, GAAP
46.18
45.71
46.26
43.57
42.44
39.78
39.33
29.23
29.94
29.31
29.49
29.64
29.93
27.39
27.48
26.89
22.05
Effective Tax Rate (%)
2.29
2.42
2.77
2.85
2.85
2.86
2.78
3.62
3.16
3.14
3.13
3.74
3.07
2.88
2.53
3.06
2.63
Profit Margin (%)
-3,804
-6,618
-11,328
-19,016
-24,265
-31,202
-32,552
-40,383
-49,111
-52,785
-47,800
-34,412
-46,592
-54,968
-58,896
-55,058
-62,813
Working Capital
6,657
4,360
2,803
1,951
4,390
11,734
20,099
15,504
12,172
10,698
9,029
7,349
6,357
13,716
27,551
42,019
21,344
LT Debt
24,409
29,691
36,380
44,950
54,399
65,055
76,179
93,053
108,888
126,289
145,675
170,578
190,507
211,072
231,442
257,463
243,486
Total Equity
12.01
13.98
16.6
17.7
16.19
13.45
11.58
13.75
12.66
12.61
13.11
13.04
10.54
9.93
8.98
9.98
4.74
Return on Invested Capital (%)
17.24
18.62
22.34
23.14
21.06
17.43
14.16
17.49
15.23
14.93
14.85
16.48
12.46
11.34
10.11
11.07
5.26
Return on Capital (%)
26.44
25.31
27
25.9
23.39
21.11
18.75
22.67
18.24
16.93
16.28
17.66
13.14
12.12
11.29
12.94
5.66
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
May'24
Aug'25
Nov'25
ST Debt
6,512
- -
4,331
LT Borrowings
23,385
- -
21,344
LT Finance Leases
4,166
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
- -
79
Market Capitalization
612,542
455,454
466,645

Working Capital

FRC

•

in mil. unless spec.
May'24
Aug'25
Nov'25
Total Current Assets
154,333
- -
150,020
Cash, Cash Equivalents & STI
52,301
- -
39,129
Accounts Receivable, Net
637
- -
683
Inventories
86,173
- -
93,850
Total Current Liabilities
213,229
- -
212,833
Payables & Accruals
- -
- -
- -
ST Debt
6,512
- -
4,331
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.81%
12.09%
11.24%
Free Cash Flow
-841.49%
-212.28%
35.28%
Net Income, GAAP
11.43%
8.83%
26.68%
Sales/Revenue/Turnover
9.55%
8.22%
4.81%
Total Cash Common Dividend
- -
- -
6.44%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
241,653
234,777
238,881
249,678
964,989
2025
- -
- -
- -
- -
1,011,390
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
82.18
- -
- -
- -
308.61
2025
- -
- -
- -
- -
390.86
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
58.8
2025
- -
- -
- -
- -
62.57
2026
- -
- -
- -
- -
- -
Similar Companies
Nahdi Medical Company (4164.SR)
GABY Inc. (GABY.CN)
Ji Yao Holding Group Co., Ltd. (300108.SZ)
Eastgate Biotech Corp. (ETBI)
Beihai Gofar Chuanshan Biological Co., Ltd. (600538.SS)
Endo International plc (0Y5F.L)
Business
COSMOS Pharmaceutical Corporation operates a chain of drugstores in Japan under the Drugstore Cosmos banner, offering pharmaceuticals, cosmetics, daily necessities, general food products, and other retail items. The company retails general medicines, health drinks, vitamins, health foods, dietary supplements, prescription drugs, and nursing care products; cosmetics including skin care, hair care, and bath additives; miscellaneous goods such as detergents, insecticides, toiletries, kitchenware, gardening supplies, clothing, and car-related items; general food encompassing processed foods, seasonings, bread, pastries, dairy products, beverages, and liquor; as well as tobacco and cigarettes. It maintains a dense network of large-format stores, known as small-catchment-area mega drugstores, primarily in Kyushu, Chugoku, Shikoku, Kansai, Chubu, and Kanto regions, emphasizing everyday low pricing, one-stop shopping convenience, and high product quality through direct manufacturer collaborations. Founded in 1983 and headquartered in Fukuoka City, Japan, COSMOS Pharmaceutical employs over 5,000 full-time staff alongside temporary workers and operates 1,546 stores as of late 2024 through subsidiaries including COSMOS Corporation and Green Flash Corporation. Recent developments include a 2-for-1 stock split in August 2024 to enhance liquidity, accelerated store openings targeting around 100 new locations annually amid leadership in large drugstore expansions, selection of RELEX Solutions in 2025 for AI-driven supply chain optimization across stores and logistics, and sustained revenue growth with Q1 2025 sales exceeding forecasts.